• A Omlin, C J Pezaro, S Zaidi, D Lorente, D Mukherji, D Bianchini, R Ferraldeschi, S Sandhu, D Dearnaley, C Parker, N Van As, J S de Bono, and G Attard.
• Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
• Br. J. Cancer. 2013 Sep 3; 109 (5): 1079-84.

BackgroundAbiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).MethodsCastration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.ResultsTwo-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.ConclusionAbiraterone has important antitumour activity in men with CRPC even after DES exposure.

30 keywords...

hide…